
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Inpatient Management of Adults With Inflammatory Bowel Disease: Expert Review</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "‚ñ∂";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on Inpatient Management of Adults With Inflammatory Bowel Disease: Expert Review</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Gastroenterology 2026;170:408‚Äì417</li><li>- This review provides <u>Best Practice Advice</u> on the evaluation and management of hospitalized adult patients with IBD.</li></ul>
                
        <details>
            <summary><strong>üí° Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended daily dose equivalent of intravenous methylprednisolone for severe UC?</li><li>- What CRP level in a patient with ASUC should trigger the initiation of IV corticosteroids?</li><li>- What is the number needed to treat with prophylactic anticoagulation to prevent one VTE event in hospitalized IBD patients?</li><li>- For how long can IV corticosteroid treatment be continued in a non-responsive UC patient before it provides no incremental benefit?</li><li>- What is the threshold size for an intra-abdominal abscess in Crohn's disease that typically warrants percutaneous drainage?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üè• Indications for Hospitalization (BPA 1)</strong></summary>
            <div>
                <ul><li>- Consider prompt hospitalization for patients with <u>severe disease refractory to outpatient treatment</u>.</li><li>- Also indicated for high suspicion of IBD-related complications or significant nutritional risk.</li></ul>
                
        <details>
            <summary><strong>Key Presentations Warranting Admission</strong></summary>
            <div>
                <ul><li>- <b>Uncontrolled inflammation</b> unresponsive to outpatient therapy.</li><li>- <b>Suspicion of complications</b> like intestinal obstruction, perforation, or intra-abdominal abscess.</li><li>- <b>Severe symptoms/conditions</b> requiring inpatient care:</li><li>- Dehydration and electrolyte derangements.</li><li>- Short bowel syndrome.</li><li>- Uncontrolled pain.</li><li>- Severe anemia requiring transfusions.</li><li>- Severe malnutrition requiring enteral or parenteral nutrition.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Acute Severe Ulcerative Colitis (ASUC)</strong></summary>
            <div>
                <ul><li>- ASUC is a traditional indication for urgent hospitalization for IV corticosteroid therapy and exclusion of infection.</li></ul>
                
        <details>
            <summary><strong>Truelove and Witts Criteria</strong></summary>
            <div>
                <ul><li>- Defined as <q><u>6 or more bloody bowel movements daily</u></q> AND at least one systemic sign.</li></ul>
                
        <details>
            <summary><strong>Systemic Signs</strong></summary>
            <div>
                <ul><li>- <b>Tachycardia:</b> Heart rate <q>>90 beats/min</q></li><li>- <b>Fever:</b> Temperature <q>>37.8 ¬∞C</q></li><li>- <b>Anemia:</b> Hemoglobin <q><10.5 g/dL</q></li><li>- <b>Elevated ESR:</b> <q>>30 mm/h</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prognostic Value</strong></summary>
            <div>
                <ul><li>- These criteria predict the risk of progression to colectomy.</li><li>- Colectomy rates rise from <q>8.5% to 48%</q> based on the number of criteria met.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of C-Reactive Protein (CRP)</strong></summary>
            <div>
                <ul><li>- CRP has a shorter half-life than ESR and is more responsive to acute inflammation.</li><li>- It has largely replaced ESR as a real-time inflammatory biomarker and predictor of colectomy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Modern Hospitalization Trends</strong></summary>
            <div>
                <ul><li>- Patients are now more likely hospitalized for IBD refractory to <u>multiple steroid-sparing immune therapies</u> rather than a classic fulminant ASUC presentation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üìã Initial Inpatient Management (BPA 2 & 3)</strong></summary>
            <div>
                <ul><li>- Initial management should include supportive care and evaluation for complications and infections.</li></ul>
                
        <details>
            <summary><strong>Supportive Care (BPA 2)</strong></summary>
            <div>
                <ul><li>- Perform a standard assessment with an IBD-tailored history, physical exam, and laboratory testing.</li></ul>
                
        <details>
            <summary><strong>Core Supportive Measures</strong></summary>
            <div>
                <ul><li>- <b>IV hydration</b> and electrolyte repletion.</li><li>- Treatment for acute <b>anemias</b>.</li><li>- <b>Pain control</b> as needed.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Nutritional Support</strong></summary>
            <div>
                <ul><li>- Screen all patients for malnutrition using validated tools (e.g., <u>Malnutrition Universal Screening Tool</u>).</li><li>- Refer to a dietitian for a complete evaluation if indicated.</li><li>- Screen for vitamin deficiencies, especially <q><b>B12</b> and <b>D</b></q>, and iron deficiency.</li></ul>
                
        <details>
            <summary><strong>IV Iron Therapy</strong></summary>
            <div>
                <ul><li>- Consider for patients with active inflammation, moderate to severe anemia (especially Hb <q><10 g/dL</q>), or intolerance to oral iron.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pain Management Strategy</strong></summary>
            <div>
                <ul><li>- Data suggests <q>1 in 4</q> hospitalized IBD patients receive inadequate pain control.</li><li>- <b>Address underlying factors:</b> NG decompression for obstruction, abscess drainage, treating inflammation.</li><li>- Use a <u>sequential stepped approach</u> and shared decision-making.</li><li>- <b>Avoid Opioids:</b> Due to risks of narcotic bowel syndrome and addiction.</li><li>- <b>Caution with NSAIDs:</b> Potential to exacerbate intestinal ulceration.</li><li>- <b>Consider Neuromodulators:</b> Tricyclic antidepressants, SNRIs, and mirtazapine have shown efficacy for chronic GI pain.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Evaluation for Complications & Infections (BPA 3)</strong></summary>
            <div>
                <ul><li>- A significant portion of IBD symptom flares are driven by concomitant gastrointestinal infections.</li></ul>
                
        <details>
            <summary><strong>Infection Testing</strong></summary>
            <div>
                <ul><li>- <b>Stool Pathogens:</b> Test all patients with diarrhea with stool culture and <u>C. difficile toxin testing</u> (using a 2-step approach).</li><li>- <b>Cytomegalovirus (CMV):</b> Evaluate for CMV in patients with worsening symptoms, systemic toxicity, or lack of response to corticosteroids.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Imaging for Complications</strong></summary>
            <div>
                <ul><li>- <b>Ulcerative Colitis:</b></li><li>- For suspected toxic megacolon (>6 cm transverse colon dilation), get a timely <u>abdominal film and/or CT scan</u> and consult colorectal surgery.</li><li>- <b>Crohn's Disease:</b></li><li>- For suspected bowel obstruction or abscess, perform <u>cross-sectional imaging (MR or CT)</u> with IV contrast.</li><li>- <b>Intestinal Ultrasound:</b> Evolving evidence for its use as a diagnostic or monitoring tool for suspected bowel obstruction.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üìä Disease Activity Assessment (BPA 4)</strong></summary>
            <div>
                <ul><li>- Assess disease activity with both biomarkers and endoscopic evaluation when indicated.</li></ul>
                
        <details>
            <summary><strong>Biomarkers</strong></summary>
            <div>
                <ul><li>- Objective serologic markers can assess disease activity at presentation.</li></ul>
                
        <details>
            <summary><strong>Serologic Markers</strong></summary>
            <div>
                <ul><li>- <b>CRP:</b> Valuable for predicting colectomy risk. A CRP <q><u>‚â•1.2 mg/dL</u></q> (or ‚â•12 mg/L) has an 85% positive predictive value for severe disease.</li><li>- <b>Other markers:</b> Leukocyte count, platelet count, and albumin.</li><li>- <b>CRP to Albumin Ratio:</b> A high ratio is independently predictive of active disease.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fecal Calprotectin</strong></summary>
            <div>
                <ul><li>- Strongly correlates with endoscopic disease activity.</li><li>- <b>Limitation:</b> Processing can take up to <q>7 days</q>, limiting its utility in the acute inpatient setting.</li><li>- A baseline measurement can be valuable for later trending.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic Evaluation</strong></summary>
            <div>
                <ul><li>- Early endoscopy is important for assessing inflammation severity and obtaining biopsies.</li></ul>
                
        <details>
            <summary><strong>Procedure & Timing</strong></summary>
            <div>
                <ul><li>- A <b>flexible sigmoidoscopy</b> with limited or no prep is often sufficient.</li><li>- Early endoscopy (within <q><u>48 hours</u></q> of admission) is associated with decreased length of stay and hospital costs.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Ruling out CMV</strong></summary>
            <div>
                <ul><li>- In cases of systemic toxicity, corticosteroid non-response, or ASUC, obtain mucosal biopsies to exclude CMV infection.</li><li>- Diagnosis requires histologic examination (H&E stain with immunohistochemistry).</li><li>- <b>Treatment Criteria:</b> Limit treatment to patients with clinically active IBD, high-density histologic CMV (<q><u>5 or more inclusions</u></q>), and non-response to corticosteroids.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üíâ VTE Prophylaxis (BPA 5)</strong></summary>
            <div>
                <ul><li>- Hospitalized patients with IBD have a <q><u>2-fold increased risk</u></q> of venous thromboembolism (VTE).</li><li>- Inflammation and corticosteroid use contribute to a hypercoagulable state.</li></ul>
                
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>- <b>All hospitalized IBD patients</b> without absolute contraindications should receive prophylactic anticoagulation.</li><li>- Options include subcutaneous low-molecular-weight heparin or fondaparinux.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Prophylaxis is effective at reducing VTE events.</li><li>- <b>Number Needed to Treat (NNT):</b> <q>35</q></li><li>- <b>Number Needed to Harm (NNH) for major bleeding:</b> <q>114</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Discharge Prophylaxis</strong></summary>
            <div>
                <ul><li>- Decision to continue after discharge should be individualized for high-risk patients (e.g., recent surgery, active malignancy, immobilization).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üî• Management of Severe Ulcerative Colitis (ASUC)</strong></summary>
            <div>
                <ul><li>- A multi-faceted approach involving surgical consultation, medical therapy, and close monitoring is crucial.</li></ul>
                
        <details>
            <summary><strong>Surgical Consultation & Counseling (BPA 6)</strong></summary>
            <div>
                <ul><li>- Overall, <q><b>10%</b></q> of hospitalized patients with UC will require surgery.</li><li>- Engage the surgical team <u>early</u> during hospitalization and counsel patients on the potential need for colectomy.</li></ul>
                
        <details>
            <summary><strong>Toxic Megacolon</strong></summary>
            <div>
                <ul><li>- A highly morbid complication presenting with acute colonic dilation (<q>>6 cm</q>) and systemic toxicity.</li><li>- Often requires <b>emergent surgery</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Perioperative Management</strong></summary>
            <div>
                <ul><li>- Consider transfer to a high-volume IBD center for non-responders.</li><li>- Recent data suggests <u>no beneficial role</u> for perioperative stress-dose corticosteroids.</li><li>- Follow an <b>Enhanced Recovery After Surgery (ERAS)</b> protocol.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Initial Medical Therapy (BPA 7)</strong></summary>
            <div>
                <ul><li>- First-line therapy for most hospitalized severe UC patients is <b>intravenous corticosteroids</b>.</li></ul>
                
        <details>
            <summary><strong>Dosing</strong></summary>
            <div>
                <ul><li>- Optimal dose is methylprednisolone <q><b>40‚Äì60 mg</b></q> daily equivalent.</li><li>- A dose of <q><b>60 mg</b></q> daily is common practice.</li><li>- Doses <q><u>>60 mg/day</u></q> confer no additional benefit and increase adverse effects.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Important Considerations</strong></summary>
            <div>
                <ul><li>- Initiation should <u>not be delayed</u> while awaiting pathogen testing results.</li><li>- Should not be discontinued if C. difficile or CMV are detected, as long as pathogen-specific treatment is initiated concurrently.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring Treatment Response (BPA 8)</strong></summary>
            <div>
                <ul><li>- Response to medical therapy should be assessed within <q><b>72 hours</b></q> of initiation.</li></ul>
                
        <details>
            <summary><strong>Oxford Criteria (Day 3 Assessment)</strong></summary>
            <div>
                <ul><li>- Assess changes in stool frequency and CRP on day 3 of corticosteroid treatment.</li><li>- Predicts future colectomy risk.</li></ul>
                
        <details>
            <summary><strong>High Risk for Colectomy</strong></summary>
            <div>
                <ul><li>- <q><b>85%</b></q> of patients will require colectomy if on day 3 they have either:</li><li>- <q><u>8 or more</u></q> bowel movements daily, OR</li><li>- <q><u>3‚Äì8 bowel movements</u></q> daily with a CRP <q><b>>4.5 mg/dL</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Duration of Steroid Trial</strong></summary>
            <div>
                <ul><li>- Continuing IV corticosteroid treatment beyond <q><b>7 days</b></q> in non-responders provides <u>no incremental benefit</u> and increases risk of complications and mortality.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Intestinal Ultrasound</strong></summary>
            <div>
                <ul><li>- An emerging tool for monitoring response.</li><li>- Significant changes in bowel wall thickness can be seen as early as <q>48 hours</q> after starting corticosteroids in responders.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Rescue Therapy for Non-Responders (BPA 9)</strong></summary>
            <div>
                <ul><li>- Preparations for rescue or salvage therapies should be initiated <u>early</u> in the admission for patients not responding to IV corticosteroids.</li></ul>
                
        <details>
            <summary><strong>Medication Options</strong></summary>
            <div>
                <ul><li>- <b>Infliximab</b></li><li>- <b>Cyclosporine</b></li><li>- <b>Janus Kinase (JAK) inhibitors</b> (e.g., tofacitinib, upadacitinib)</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Infliximab Dosing</strong></summary>
            <div>
                <ul><li>- The optimal dosing for ASUC is not yet known.</li><li>- A recent study showed <u>no significant difference</u> in response between intensified (10 mg/kg or accelerated induction) vs. standard (5 mg/kg) dosing.</li><li>- Consider accelerated dosing (e.g., <q>10 mg/kg</q>) for patients at risk of treatment failure due to protein-losing colopathy (low albumin, high CRP).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>JAK Inhibitors</strong></summary>
            <div>
                <ul><li>- Optimal dose is unknown, but both standard and off-label high-intensity doses have been used effectively.</li><li>- <b>Vaccination:</b> Patients should receive a varicella zoster vaccine, but treatment initiation should not be delayed. The recombinant vaccine can be given after starting the JAK inhibitor.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üå™Ô∏è Management of Crohn's Disease Complications</strong></summary>
            <div>
                <ul><li>- Inpatient management often focuses on complications like obstruction, abscesses, and perianal disease.</li></ul>
                
        <details>
            <summary><strong>Intestinal Obstruction (BPA 10)</strong></summary>
            <div>
                <ul><li>- Patients often present with abdominal distention, nausea, and vomiting.</li></ul>
                
        <details>
            <summary><strong>Initial Management</strong></summary>
            <div>
                <ul><li>- In absence of peritonitis or ischemia:</li><li>- <b>Bowel rest</b></li><li>- <b>Nasogastric decompression</b></li><li>- <b>Intravenous fluids</b> and electrolytes.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnosis & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Imaging:</b> CT abdomen/pelvis with IV contrast (<u>without oral contrast</u>) is usually sufficient.</li><li>- <b>Medical:</b> If active inflammation is present, consider <b>IV corticosteroids</b>.</li><li>- <b>Surgical:</b> Indicated for predominantly fibrotic strictures or complications (perforation, abscess).</li><li>- Preoperatively, taper steroids to <q>prednisone 20 mg daily</q> if possible to reduce infection risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Acute Management</strong></summary>
            <div>
                <ul><li>- After resolution, consider endoscopic balloon-assisted dilation for short-segment (<q><5 cm</q>) non-inflammatory strictures.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Intra-abdominal Abscess (BPA 11)</strong></summary>
            <div>
                <ul><li>- Requires a multidisciplinary approach involving gastroenterology, colorectal surgery, and interventional radiology.</li></ul>
                
        <details>
            <summary><strong>Initial Treatment</strong></summary>
            <div>
                <ul><li>- <b>Infection Control:</b></li><li>- <b>IV antibiotics</b> with GI flora coverage (e.g., ciprofloxacin and metronidazole).</li><li>- <b>Percutaneous drainage</b> should be pursued if the abscess is <q><b>>2‚Äì3 cm</b></q>.</li><li>- <b>Urgent Surgery:</b> Required for patients with peritonitis or uncontrolled sepsis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Medical & Nutritional Therapy</strong></summary>
            <div>
                <ul><li>- Once source control is achieved, treatment with <b>steroid-sparing immune therapies</b> (e.g., anti-TNF) is acceptable.</li><li>- <b>Exclusive enteral nutrition</b> can improve outcomes in select patients with undrainable abscesses.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Active Perianal Disease (BPA 12)</strong></summary>
            <div>
                <ul><li>- Best managed with a combined medical and surgical approach.</li></ul>
                
        <details>
            <summary><strong>Core Management</strong></summary>
            <div>
                <ul><li>- <b>Surgical:</b> Examination under anesthesia, incision and drainage of abscesses, and seton placement are key immediate steps.</li><li>- <b>Imaging:</b> Contrast-enhanced CT or MR can delineate complex fistula tracts.</li><li>- <b>Optimal Therapy:</b> The combination of <u>surgery, antibiotics, and <b>anti-TNF therapy</b></u> is considered the optimal approach.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Refractory Disease</strong></summary>
            <div>
                <ul><li>- For severe refractory disease, a diverting colostomy or ileostomy can be a temporizing measure.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>üîö Discharge Planning (BPA 13)</strong></summary>
            <div>
                <ul><li>- A clear discharge transition plan is critical to prevent common and costly readmissions.</li></ul>
                
        <details>
            <summary><strong>Discharge Criteria</strong></summary>
            <div>
                <ul><li>- Discharge is appropriate after <b>resolution or stabilization</b> of the acute admission indication.</li><li>- Does <u>not</u> necessarily require normalization of inflammatory biomarkers (e.g., CRP) or imaging findings.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Transition Plan Components</strong></summary>
            <div>
                <ul><li>- <b>Communication:</b> Identify and communicate with responsible outpatient clinicians.</li><li>- <b>Patient Education:</b> Provide clear instructions on corticosteroid tapering, outpatient infusion scheduling, and when to contact the medical team.</li><li>- <b>Address Barriers:</b> Proactively manage social determinants like prior authorizations, medication affordability, and transportation challenges.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
